Mark Murray, MD
Allergy & Immunology · Diberville, MSNPI 1669594974
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,075 of the $40,963 with a category attached, or 83.2%. GSK accounts for 87.2% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $13,293 and has fallen 90.0% since, to $1,328 in 2025.
Across 393 payments — averaging $104.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$36K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$631
- Amgen$509
- AstraZeneca$464
- Sanofi$443
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$34,07583%
- Travel & lodging$1900%
- Food & beverage$6,51416%
- Education$1840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $35,708 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,023 |
| Genentech USA, Inc. | 32 | $631 |
| Amgen | 33 | $509 |
| AstraZeneca | 27 | $464 |
| Sanofi | 23 | $443 |
| Kaleo, Inc. | 27 | $381 |
| Pfizer | 19 | $305 |
| CSL Behring | 15 | $248 |
| Novartis | 12 | $212 |
| Teva Pharmaceuticals USA, Inc. | 11 | $186 |
| Lilly USA, LLC | 3 | $145 |
| Grifols USA, LLC | 7 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Biocryst US Sales Co., LLC | 3 | $63 |
| AbbVie | 2 | $51 |
| Galderma Laboratories, L.p. | 3 | $49 |
| Boehringer Ingelheim | 3 | $37 |
| Merck | 2 | $36 |
| LEO Pharma Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Optinose US, Inc. | 2 | $33 |
| Organon | 1 | $33 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Dermavant Sciences, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Biocryst Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$34,431
How this compares
$40,963 in reported general payments places this provider in the 80th percentile of 28 allergy & immunology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 20 | $76,891 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 27 | $71,927 |
| Dupixent PenDupilumab | 12 | $37,516 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,835 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,265 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,370 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,030 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,986 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,109 |
| Azelastine Hcl | 64 | $2,807 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,229 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,035 |
| Ipratropium Bromide | 23 | $1,287 |
| Montelukast Sodium | 138 | $1,263 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $35,708 | $37,32972 claims |
| Boehringer IngelheimSpiriva Respimat | $37 | $10,37011 claims |
| AstraZenecaSymbicort | $464 | $4,03016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 allergy & immunology providers in Mississippi.
Other allergy & immunology in Diberville
- Todd AdkinsJackson$226K
- Patricia StewartMadison$215K
- Daniel VenarskeJackson$156K
- Dexter WalcottJackson$154K
- Chelle WilhelmJackson$61K
- Stephen LeblancMeridian$34K
- Jennifer OlivierPicayune$24K
- Joshua PhillipsJackson$20K
- Matthew OswaltTupelo$13K
- Karen MaltbyTupelo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.